Richard S. Geary

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 748 citations

Medicine, Pharmacology, Clinical Pharmacology +6

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Joseph L. Witztum, Daniel Gaudet, Steven D. Freedman et al. · New England Journal of Medicine · 2019 · 669 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides

Mark J. Graham, Richard Lee, Teresa Brandt et al. · New England Journal of Medicine · 2017 · 581 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Daniel Gaudet, Veronica Alexander, Brenda F. Baker et al. · New England Journal of Medicine · 2015 · 528 citations · Full text

Medicine, Biochemistry, Pharmacology +14

Targeting APOC3 in the Familial Chylomicronemia Syndrome

Daniel Gaudet, Diane Brisson, Karine Tremblay et al. · New England Journal of Medicine · 2014 · 493 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17